News | November 23, 2008

Deborah Heart and Lung Center Begins Using Impella Device for High-Risk Cath Lab Patients

November 24, 2008 - Deborah Heart and Lung Center in Browns Mills, NJ said this week it successfully debuted the new Impella LP 2.5 minimally-invasive, catheter-based cardiac assist device in high-risk patients undergoing cardiac interventions.

The Impella 2.5, made by Abiomed, received FDA approval in June and is the world’s smallest heart pump. It is inserted through the skin in the cath lab via the femoral artery into the left ventricle of the heart. Up to 2.5 liters of blood per minute can then be continuously pumped from the left ventricle into the ascending aorta, providing the heart with active support in critical situations. With this steady blood flow, patients who were too critical to receive a cardiac intervention can now have life-saving treatment, Deborah officials said. Deborah is the first hospital in south Jersey to use this technology.

“Our first use of the Impella device for high risk PCI went very smoothly and successfully,” said Dr. Tommy Ng who heads up Deborah’s Impella team. “This offers a wide range of possibilities for patients who previously were not candidates for a cardiac intervention. This device has the potential to bring a fundamental shift for patients in the cath lab.”

“We are excited about this new technology,” said Dr. Manu Rajachandran, director of Deborah’s cardiac catheterization laboratory. “This will give us the ability to reach patients who were previously too medically fragile to undergo procedures which could save their lives. It is gratifying once again to be at the cutting-edge in medicine.”

Deborah Heart and Lung Center is a 139-bed teaching hospital that specializes in the diagnosis and treatment of congenital and acquired heart, lung and vascular diseases in adults, as well as providing outpatient cardiology services for children.

For more information:

Related Content

FDA Confirms Impella RP is Safe and Effective
News | Ventricular Assist Devices (VAD) | June 12, 2019
 In a letter sent to healthcare providers, the U.S. Food and Drug Administration (FDA) validates that Abiomed’s Impella...
Impella SmartAssist Platform Launches at SCAI
News | Ventricular Assist Devices (VAD) | May 22, 2019
Abiomed announced that the Impella CP with SmartAssist will be commercially available beginning at the 2019 Society for...
FDA Approves Impella 5.0 and Impella LD Extended Duration of Use
Technology | Ventricular Assist Devices (VAD) | May 14, 2019
The U.S. Food and Drug Administration (FDA) has approved the expansion of Abiomed’s Impella 5.0 and Impella LD...
FDA Approves Initiation of STEMI DTU Pivotal Randomized Controlled Trial
News | Ventricular Assist Devices (VAD) | May 02, 2019
Abiomed announced that, on April 26, the U.S. Food and Drug Administration (FDA) approved initiation of the ST-...
Cardiogenic Shock Survival Rates Improve in Three Years Since Impella FDA Approval
News | Ventricular Assist Devices (VAD) | April 05, 2019
Three years ago this week, Abiomed's Impella heart pump received U.S. Food and Drug Administration (FDA) premarket...
HeartMate 3 Pump Shows Superior Outcomes in Advanced Heart Failure
News | Ventricular Assist Devices (VAD) | March 22, 2019
Severely ill patients with advanced heart failure who received the HeartMate 3 left ventricular assist device (LVAD)...
Leviticus Cardio and Jarvik Heart Unveil Wireless Heart Pump System
News | Ventricular Assist Devices (VAD) | February 11, 2019
Heart failure experts at the National Research Center for Cardiac Surgery in Astana, Kazakhstan, recently announced the...
Medtronic Receives FDA Approval for Less-Invasive Heart Pump Implant Procedure
Technology | Ventricular Assist Devices (VAD) | July 17, 2018
Medtronic plc recently received U.S. Food and Drug Administration (FDA) approval for a less-invasive implant approach...
CorWave's Next-generation Neptune LVAD Receives Funding

Image courtesy of CorWave

News | Ventricular Assist Devices (VAD) | July 11, 2018
French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new...
Overlay Init